

PharmLabs San Diego Certificate of Analysis

Sample DELTA STATE - PREMIUM - GORILLA GLUE



Delta9 THC UI	THCa 6.49%	Total THC (THCa * 0.877 + THC) 5.69%	Delta8 THC 41.00%
---------------	------------	--------------------------------------	-------------------

Sample ID SD250324-063 (110269)	Matrix Concentrate
Tested for A8 Industries	
Sampled -	Received Mar 24, 2025
Analyses executed CANX, PRY	Reported Mar 26, 2025

Laboratory note: The Δ9-THC results in this particular sample is inconclusive due to potential interferences from several cannabinoids when analyzed using our GC MS/MS D9C method. As a result, this sample will not undergo testing via the GC MS/MS D9C method. However, there are currently no interferences detected with any other cannabinoids in this sample when employing HPLC.

CANx - Cannabinoids

Analyzed Mar 25, 2025 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.806% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g
11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND
Cannabidiolcin (CBDO)	0.006	0.02	ND	ND
Abnormal Cannabidiolcin (a-CBDO)	0.013	0.038	ND	ND
(±)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	0.11	1.09
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND
Δ8-tetrahydrocannabivarin (Δ8-THCV)	0.012	0.036	0.30	2.98
Cannabidihexol (CBDH)	0.014	0.042	ND	ND
Tetrahydrocannabutol (Δ9-THCB)	0.01	0.029	ND	ND
Cannabinol (CBN)	0.047	0.16	0.81	8.06
Cannabidiaphoral (CBDP)	0.016	0.049	ND	ND
exo-THC (exo-THC)	0.005	0.16	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	41.00	410.03
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	5.29	52.87
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	11.64	116.35
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	6.49	64.90
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.02	0.061	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND
Δ9-Tetrahydrocannabiphoral (Δ9-THCP)	0.017	0.8	8.45	84.53
Δ8-Tetrahydrocannabiphoral (Δ8-THCP)	0.041	0.8	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	5.97	59.70
9(R)-HHCP (r-HHCP)	0.015	0.045	2.95	29.54
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			5.69	56.92
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			46.69	466.95
Total CBD (CBDA * 0.877 + CBD)			0.10	0.96
Total CBG (CBGa * 0.877 + CBG)			ND	ND
Total HHC (9r-HHC + 9s-HHC)			16.92	169.22
Total Cannabinoids Analyzed			82.19	821.93

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



DCC license: C8-0000098-LIC
DEA license: RP0611043
ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
Wed, 26 Mar 2025 14:03:33 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



"This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.